UNSPSC 51343117: Idoxuridine monohydrate

This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11IN2O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E78KL7PVW, chemically known as uridine, 2'-deoxy-5-iodo-, monohydrate, but more generally known as idoxuridine monohydrate, which bears US NIH Compound Identifier 28330. European Medicines Agency schedules idoxuridine monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08117MIG.

Most nations, for tariff purposes, schedule idoxuridine monohydrate under HS 29349990. SMILES: C1C(C(=O)[NH]C(=O)N1[C@H]2C[C@@H]([C@H](O2)CO)O)I.O.

UNSPSC 51343117 Idoxuridine monohydrate is a Commodity code identifying a specific antiviral pharmaceutical product, but the recent state and local contract opportunities tagged under this code do not reflect procurement of idoxuridine itself. Instead, the opportunities show state and local health and emergency-management agencies sourcing broader pharmaceutical and medical-supply categories through piggyback contracts and competitive bidding — including antibiotics, naloxone, and drug deactivation systems. The scope divergence suggests either miscoding or use of the code as a placeholder within broader pharmaceutical procurement frameworks. State and local buying under pharmaceutical codes at this tier typically encompasses emergency stockpiling, public-health interventions, and pharmacy warehouse supply agreements. The issuing bodies include state departments of public health executing multi-year supply contracts through cooperative purchasing consortia, and county health and emergency-management divisions conducting fixed-term procurements for community health initiatives.

The recent activity spans Illinois and Florida, with the Illinois Department of Public Health awarding a $2,999,999.11 three-year piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for antibiotics (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets) via Invitation for Bid; and Seminole County, Florida releasing an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries required to the Seminole County Community Health Building. Neither opportunity reflects active procurement of idoxuridine monohydrate specifically, limiting the code's apparent relevance to current state and local buying patterns.